Results of a large-scale international survey, released by the World Lupus Federation on World Lupus Day May 10, show a low level of lupus awareness by the general public, revealing a need for increased education and understanding about the disease.
Lupus is considered to be a global health problem, with more than 5 million people estimated to have the condition worldwide. Despite this, key findings from the survey, which included 35,506 people in 16 countries, showed that more than half the respondents were not aware that lupus is a disease. Among those who did recognize lupus as a disease, nearly half over the age of 55 did not know of any complications associated with the condition.
ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by high unmet medical need, low marketing costs, relatively low development costs. Their flagship drug, Lupuzor™, a potential treatment for Lupus has completed dosing patients across US, Europe and Mauritius and has announced top line results for the Phase 3 trial.